GOLD LEVEL SPONSORS
Pfizer Oncology is committed to pursuing innovative treatments that have a meaningful impact on people living with cancer. Our growing pipeline of biologics, small molecules, and immunotherapies is focused on identifying and translating the best scientific breakthroughs into clinical application for patients across a diverse array of solid tumors and hematologic cancers. Today, we have 10 approved oncology medicines and 14 assets currently in clinical development. By maximizing our internal scientific resources and collaborating with other companies, government and academic institutions, as well as patients and non-profit and professional organizations, we are bringing together the brightest and most enterprising minds to take on the toughest cancers. Together we can accelerate breakthrough treatments to patients around the world and work to redefine life with cancer.
To learn more, please visit: www.Pfizer.com
SILVER LEVEL SPONSORS
Blue Earth Diagnostics is a molecular imaging diagnostics company focused on the development and commercialization of novel PET imaging agents to inform clinical management and guide care for cancer patients in areas of unmet medical need. Formed in 2014, Blue Earth Diagnostics is led by recognized experts in the clinical development and commercialization of innovative nuclear medicine products. The company’s first approved and commercially available product is Axumin® (fluciclovine F 18), a novel molecular imaging agent approved in the United States and European Union for use in PET imaging to detect and localize prostate cancer in men experiencing suspected biochemical recurrence. Blue Earth Diagnostics is funded by Syncona, an investment company listed on the London Stock Exchange (LON: SYNC).
To learn more, please visit www.blueearthdiagnostics.com.
Royal Philips of the Netherlands is a diversified technology company, focused on improving people’s lives through meaningful innovation in the areas of Healthcare, Consumer Lifestyle and Lighting. Philip’s commitment is to deliver new healthcare and lighting technologies, as well as innovative and locally relevant consumer products that make a real difference to our customers, consumers and stakeholders across the globe.
To learn more, please visit: www.philips.com/global
Invivo is a business of Royal Philips (NYSE: PHG; AEX: PHIA) and has an over 20-year history as the pioneer of progressive MRI coils, advanced clinical visualization systems, and MRI-compatible interventional devices.
To learn more, please visit http://www.invivocorp.com/
To learn more, please visit
BRONZE LEVEL SPONSORS
Exact Imaging’s ExactVu™ 29 MHz micro-ultrasound platform provides a 300% improvement in resolution over conventional ultrasound enabling real-time targeted prostate biopsies. It is simple, affordable, and an extension of the current urological workflow. For the minority of cases where MRI might assist, the FusionVu™ micro-US/MRI fusion application operates on the same platform – – and is guided by the real-time 70 micron resolution of the ExactVu system.
To learn more, please visit http://www.exactimaging.com/
Our Vision: To revolutionize the treatment of cancer throughout the patient journey.
Hitachi Healthcare offers a complete range of diagnostic imaging solutions, designed around the patient, for the patient. Our innovative systems afford you the flexibility to tailor imaging to the individual patient, while delivering superb image quality safely and efficiently. We proudly continue to top the MD Buyline user satisfaction ratings and we intend to continue earning your trust every day.
Please visit us at www.hitachihealthcare.com
Myriad is focused on revolutionizing patient care through the discovery, development and marketing of transformative molecular diagnostic tests that address pressing clinical needs across multiple medical specialties. Myriad has invested heavily in educating patients and healthcare professionals about the role genes and proteins play in disease. Today, Myriad is expanding its reach and increasing its impact on patient care by introducing new molecular diagnostic and companion diagnostic tests for a growing number of diseases.
To learn more, please visit
SOTIO is developing innovative therapies that harness the immune system and focus primarily on immuno-oncology, effectively translating science into patient benefit.
Canon Medical Systems USA, Inc., headquartered in Tustin, Calif., markets, sells, distributes and services radiology and cardiovascular systems, including CT, MR, ultrasound, X-ray and interventional X-ray equipment. For more information, visit Canon Medical Systems’ website at https://us.medical.canon.
Clinical Laserthermia Systems (CLS) develops and sells the TRANBERG® Thermal Therapy System, an advanced medical device for minimally invasive, soft tissue thermal therapy and ablation. The TRANBERG System uses MRI images and real time thermometry for precision guidance throughout a procedure. Clinical centers in the U.S. are currently using the Tranberg system for the treatment of prostate cancer and other soft tissue disorders. CLS is headquartered in Lund Sweden with a subsidiary in Boston, MA.
To learn more, please visit: https://clinicallaser.se/en/
Desert Medical Imaging is built on the goals of providing personalized care to our local community and making the latest advances in medical imaging accessible and affordable to our patients. We believe that educated patients play a critical role in their own care and treatment, and we offer many tools and resources, in addition to our customer-friendly staff and radiologists, to help each patient make informed decisions regarding their health and care. Contact your nearest center to schedule an appointment or to learn more about how Desert Medical Imaging can help improve your health and wellness.
To learn more, please visit: www.desertmedicalimaging.com
Established in 1975 in Northern California, Eigen is improving healthcare and quality of life through innovative breakthroughs in image-guided disease diagnosis and treatment. With a focus on research & development and medical device manufacturing, Eigen currently holds over 50 patents.
Eigen adheres to the highest standard in medical device regulatory compliance. Eigen places great importance on effective risk management, as well as the best practices specific to safe medical device design, manufacture and installation. Eigen prides itself on providing excellent training to the doctors using our device. Eigen is FDA cleared, CE and TGA approved and has ISO 13485 certification.
Eigen’s MRI/US fusion, PET-CT/US fusion and 3D robotic navigation technology has been validated by multiple reputed universities worldwide and its results published in many top peer-reviewed journals. Eigen’s technology allows for accurate targeting, recording and sampling of lesions for diagnosis as well as for follow up in active surveillance or focal therapy.
The Profound Medical team is committed to the effort to achieve a new therapeutic standard in prostate cancer. Our mission is to profoundly change the standard of care by creating a tomorrow where clinicians can confidently ablate cancerous prostate tissue with precision; a tomorrow where patients have access to a safe, fast and effective treatment option, so they can quickly return to their daily lives.
Established in 2008, Profound Medical is commercializing a novel technology, TULSA-PRO®, which combines real-time Magnetic Resonance Imaging with transurethral, robotically-driven therapeutic ultrasound and closed-loop thermal feedback control that is designed to provide precise ablation of the prostate while simultaneously protecting critical surrounding anatomy from potential side effects. TULSA-PRO® is CE Marked and Profound is sponsoring a multicenter, prospective FDA-registered clinical trial, TACT.
To learn more, visit
Augmenix, Inc. is a privately held company based in the Boston area and focuses on the development and commercialization of radiation oncology products using its proprietary hydrogel technology. Focusing initially on protection during prostate radiation therapy, their next-generation products will address spacing and marking applications throughout the body to improve radiotherapy and interventional oncology procedure outcomes. SpaceOAR is a registered trademark of Augmenix, Inc. More information about Augmenix and the SpaceOAR hydrogel can be found at http://www.SpaceOAR.com.